Navigation Links
Omthera Announces Waiver of Lock-Up Restriction
Date:7/11/2013

mpleted pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova™. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova™ under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product. For more information, please visit http://www.omthera.com.

Important Information and Where to Find It

On June 13, 2013, the Company filed with the Securities and Exchange Commission (the "SEC") a definitive proxy statement in connection with the proposed transaction (the "Definitive Proxy Statement") and, on June 14, 2013, the Company commenced mailing of the Definitive Proxy Statement to its stockholders.  INVESTORS AND THE COMPANY'S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE COMPANY.  Investors and stockholders may obtain free copies of the Definitive Proxy Statement and other documents (when available) that the Company files with the SEC at the SEC's website at http://www.sec.gov.  In addition, the Definitive Proxy Statement and other documents filed by the Company with the SEC may be obtained from the Company free of charge by directing a request to Omthera Pharmaceuticals, Inc., Attn: Christian S. Schade, Executive Vice President and Chief Financial Officer, 707 State Road, Princeton, New Jersey 08540.

Certain Information Concerning Participants

The Company and its directors and executive officers and certain other persons may be deemed to be partici
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
2. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
3. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
4. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
5. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
6. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
7. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
8. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results
11. UM Ventures Announces Collaboration Between UM School Of Medicines Dr. Frank Robb and Fina Biosolutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... England , July 22, 2014 ... development and device company focused on solid dose ... its novel solid formulation of octreotide acetate achieved ... it with the currently marketed liquid product (Sandostatin®). ... transfer the formulation production process to a contract ...
(Date:7/21/2014)... /PRNewswire-iReach/ -- Nitrosolution.com, a website that features safe and ... first anniversary in August. The online retailer specializes in ... body,s ability to produce nitric oxide. Called Nitroxyl, it ... a variety of phytonutrients and other natural ingredients that ... nitric oxide production in the arteries and ...
(Date:7/21/2014)... , July 21, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... operating results for the second quarter of fiscal year ... will hold a conference call to discuss its financial ... at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern ...
Breaking Medicine Technology:Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2Thoratec Schedules Second Quarter Conference Call, Webcast 2
... 12 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... drug (IND) application to the U.S. Food and ... for rheumatoid,arthritis and other autoimmune conditions. The initial ... a double-blind, randomized,placebo-controlled, ascending single-dose study in healthy ...
... Medical Lasers Limited,(ASX: ELX), a global leader in ... systems, announced today initial clinical results of,an ongoing ... demonstrate the therapy,s potential to improve and,stabilize visual ... with,diabetic maculopathy and macular edema without causing any ...
Cached Medicine Technology:Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 2Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 2Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 3Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema 4
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... tests may one day help predict survival and the course ... also called Lou Gehrig,s disease, Italian researchers report. , , ... how fast ALS is progressing are called albumin and creatinine. ... health, according to the U.S. National Library of Medicine. ...
(Date:7/22/2014)... "right" time? How can women meet the demands of ... to become a mother has a profound effect on ... in the physical sciences. Yet many women successfully manage ... Chemistry Professor, fifteen inspirational personal accounts describe the challenges ... in chemistry. , The authors of the contributions are ...
(Date:7/22/2014)... $3 million grant to study how adverse experiences ... childhood leave molecular marks in DNA that predict ... for Biomarker Research and Personalized Medicine at the ... University School of Medicine, will conduct the five-year ... of Health, National Institute of Mental Health. , ...
(Date:7/22/2014)... heart of an astronaut is a much-studied thing. Scientists ... journal studies, even matters of the heart. But for ... stress and inflammation caused by the conditions of space ... after astronauts fly on the International Space Station. Lessons ... well. , Oxidative stress reflects an imbalance in the ...
(Date:7/22/2014)... radio-frequency identification (RFID) tags to hundreds of individual honey bees ... discoveries: Some foraging bees are much busier than others; and ... , The findings are reported in the journal ... about 20 percent of the foraging bees in a hive ... gathered to feed the hive. , "We found that some ...
Breaking Medicine News(10 mins):Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 2Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 3Health News:VCU receives grant to study molecular marks left by childhood adverse experiences 2Health News:The heart of an astronaut, five years on 2Health News:The heart of an astronaut, five years on 3Health News:Radio frequency ID tags on honey bees reveal hive dynamics 2
... ... free InkBGone products by completing a quick registration form. , ... Detroit, Mich. (PRWEB) May 19, 2010 -- StainHotline.com, an online ... Free InkBGone Ink Removal Products” by completing a short, registration form. A single 1 oz ...
... ... ... for a dentist in Kingston, NY will have a new option for their dental ... Ulster Crossing at 1159 Ulster Avenue on Thursday, May 27. The new dental practice will provide ...
... the drugs in primary care , TUESDAY, May 18 (HealthDay ... to them and stay that way for as long as ... 24 studies of antibiotic resistance, in which people develop a ... The studies looked at use of the drugs in primary ...
... better overall health could explain the link, researchers say ... French study links moderate drinking to a lower risk ... drinking gets the credit. , Instead, the researchers say, ... social status, exercise more, suffer less depression and enjoy ...
... ... but had a dilemma: They had to sell their current home, but the new residence ... problem by providing the Benjamins with a private, dignified, and stress-free home sale. , ... (PRWEB) May 19, 2010 -- Bobbie Benjamin and her ...
... , ... choice in under $100 IP phones , ... Buffalo, NY (PRWEB) May 19, 2010 -- VoIP Supply, LLC North America’s leading supplier of Voice ... IP phones on VoIPSupply.com. The Yealink line of IP phones is comprised of five ...
Cached Medicine News:Health News:Free InkBGone Stain Removal Products Being Offered By StainHotline.com 2Health News:Free InkBGone Stain Removal Products Being Offered By StainHotline.com 3Health News:New Aspen Dental Office to Open in Kingston, New York 2Health News:New Aspen Dental Office to Open in Kingston, New York 3Health News:Study Challenges Notion That Moderate Drinking Protects the Heart 2Health News:Study Challenges Notion That Moderate Drinking Protects the Heart 3Health News:Senior Home Sale Client Calls SASH's Service 'A Godsend' 2Health News:Senior Home Sale Client Calls SASH's Service 'A Godsend' 3Health News:Senior Home Sale Client Calls SASH's Service 'A Godsend' 4Health News:VoIP Supply Adds Yealink IP Phones 2
... specially rounded, extra smooth for ... manipulation in the anterior chamber. ... 25cm, ID - 1mm OD ... start .85mm from beveled ...
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... digital single plane C-arm angiography system is ... performance and an expansive range of diagnostic ... to ECG triggered. ... of the art dynamic Flat Detector technology, ...
For diagnostic and operative treatment of hand and wrist bones. The use of this distraction device allows fracture reduction or widening of the space between bones....
Medicine Products: